BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Monte Rosa Therapeutics\, Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Monte Rosa Therapeutics\, Inc's d
 rugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05546268-2661@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:MRT-2359: Phase 1/2 readout est. (NCT05546268)
DESCRIPTION:MRT-2359\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Oral MRT-2359 in Selected Cancer Patients\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mr
 t-2359#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05546268
URL:https://assetmemo.bio/drug/mrt-2359#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745361-2661@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:MRT-2359: Phase 2 readout est. (NCT07745361)
DESCRIPTION:MRT-2359\, phase 2\, Prostate Cancer.\nStudy: Study of Oral MRT
 -2359 With Apalutamide in Prostate Cancer\nEstimated primary completion: O
 ctober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mrt-2359
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 45361
URL:https://assetmemo.bio/drug/mrt-2359#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801495-10879@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:MRT-6160: Phase 2 readout est. (NCT07801495)
DESCRIPTION:MRT-6160\, phase 2.\nStudy: A Study to Assess the Efficacy\, Sa
 fety and Tolerability of DDY391 in Participants With Moderate to Severe Ps
 oriatic Arthritis\nEstimated primary completion: 13 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mrt-6160#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07801495
URL:https://assetmemo.bio/drug/mrt-6160#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07737743-10879@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20290219
DTEND;VALUE=DATE:20290220
SUMMARY:MRT-6160: Phase 2 readout est. (NCT07737743)
DESCRIPTION:MRT-6160\, phase 2\, Sjögren's Disease.\nStudy: A Phase 2a/b S
 tudy to Assess the Efficacy\, Safety and Tolerability of DDY391 in Partici
 pants With Sjögren's Disease\nEstimated primary completion: 19 February 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mrt-6160#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07737743
URL:https://assetmemo.bio/drug/mrt-6160#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923773-10879@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20291212
DTEND;VALUE=DATE:20291213
SUMMARY:MRT-6160: Phase 2 readout est. (NCT07923773)
DESCRIPTION:MRT-6160\, phase 2.\nStudy: Extension Study of Safety and Toler
 ability of DDY391 in Participants With Moderate to Severe Psoriatic Arthri
 tis (CDDY391A12201-extension)\nEstimated primary completion: 12 December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mrt-6160#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07923773
URL:https://assetmemo.bio/drug/mrt-6160#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
